< Back to previous page
Organisation
Digestive Oncology
Division
Main organisation:Department of Oncology
Lifecycle:1 Aug 2022 → Today
Organisation profile:
Digestive Oncology
Keywords:oncology
Disciplines:Oncology
Current researchers
1 - 10 of 12 results
- Sabine Tejpar (Responsible)
- Sarah Cappuyns (Member)
- Jeroen Dekervel (Member)
- Frederik Peeters (Member)
- Ting Pu (Member)
- Sabine Tejpar (Member)
- Baki Topal (Member)
- Eric Van Cutsem (Member)
- Fausto Velez Bravo (Member)
- Sara Verbandt (Member)
Projects
1 - 10 of 55
- Querying and exploiting the spatial colorectal tumor ecosystem for novel biological, diagnostic and therapeutic insightsFrom23 Nov 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The evolutionary landscape of colorectal cancer, from polyp to metastasisFrom25 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Multicenter validation trial of [18F]AlF-FAPI-74 for PET imaging of cancer-associated fibroblasts through fibroblast activation protein inhibitors (FAPI) in digestive tumorsFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimizing a high throughput TCR-epitope recognition tool to characterize microbiome specific TCR interactions in colorectal cancerFrom1 Oct 2023 → TodayFunding: BOF - doctoral mandates
- Non-genetic drivers of YAP activation in colorectal cancerFrom26 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Study the efficacy and mechanism of targeted TIM3 and VISTA in the treatment of gastroesophageal junction / gastric cancer patients with low immunogenicity and FLOT chemotherapy resistanceFrom14 Feb 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Using mucins as friends in colorectal cancer diagnostics and treatmentFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Infrastructure for Targeted ProteomicsFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Unique IsoPlexis technology for multiplexed single cell functional profilingFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Obesity-associated Hepatocellular Carcinoma at Single Cell Resolution for Risk Prediction and Novel Therapeutics - HepatoSCRIPTFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
Publications
1 - 10 of 1033
- Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies(2011)
Authors: Eric Van Cutsem
Pages: 1757 - 1764 - Napabucasin plus nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study(2021)
Authors: Eric Van Cutsem
Pages: S1084 - S1085 - Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer-an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009(2010)
Authors: Eric Van Cutsem
Pages: 1579 - 1584 - Regorafenib dose modifications in patients with metastatic colorectal cancer in the phase III CORRECT study(2013)
Authors: Eric Van Cutsem
Pages: S546 - S546 - TRASTUZUMAB WITH CHEMOTHERAPY IN UNTREATED HER2-POSITIVE ADVANCED OR METASTATIC GASTRIC CANCER: EFFICACY RESULTS FROM THE ToGA TRIAL(2009)
Authors: Eric Van Cutsem
Pages: 11 - 11 - Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009(2009)
Authors: Eric Van Cutsem
Pages: 1111 - 1118 - Lu-177-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial(2021)
Authors: Eric Van Cutsem
Pages: 1752 - 1763 - Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial(2021)
Authors: Eric Van Cutsem
Pages: 665 - 677 - Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival(2021)
Authors: Eric Van Cutsem
- Bile duct dilatation caused by the afferent loop syndrome after surgical treatment in patients with malignant diseases(2011)
Authors: Baki Topal, Dirk Vanbeckevoort, Chris Verslype, Werner Van Steenbergen
Pages: 14 - 23